262 related articles for article (PubMed ID: 24487923)
1. Monitoring the immune competence of cancer patients to predict outcome.
Chang S; Kohrt H; Maecker HT
Cancer Immunol Immunother; 2014 Jul; 63(7):713-9. PubMed ID: 24487923
[TBL] [Abstract][Full Text] [Related]
2. Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors.
Gibellini L; De Biasi S; Porta C; Lo Tartaro D; Depenni R; Pellacani G; Sabbatini R; Cossarizza A
Front Immunol; 2020; 11():490. PubMed ID: 32265933
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy.
Hartmann FJ; Babdor J; Gherardini PF; Amir ED; Jones K; Sahaf B; Marquez DM; Krutzik P; O'Donnell E; Sigal N; Maecker HT; Meyer E; Spitzer MH; Bendall SC
Cell Rep; 2019 Jul; 28(3):819-831.e4. PubMed ID: 31315057
[TBL] [Abstract][Full Text] [Related]
4. The immune contexture in cancer prognosis and treatment.
Fridman WH; Zitvogel L; Sautès-Fridman C; Kroemer G
Nat Rev Clin Oncol; 2017 Dec; 14(12):717-734. PubMed ID: 28741618
[TBL] [Abstract][Full Text] [Related]
5. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.
Chen K; Ye H; Lu XJ; Sun B; Liu Q
Trends Pharmacol Sci; 2017 Dec; 38(12):1041-1051. PubMed ID: 29089139
[TBL] [Abstract][Full Text] [Related]
6. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy.
Li X; Song W; Shao C; Shi Y; Han W
Cell Mol Immunol; 2019 Jan; 16(1):28-39. PubMed ID: 30002451
[TBL] [Abstract][Full Text] [Related]
7. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
8. Conference scene: Immune signatures in the tumor and beyond.
Kandalaft LE; Kalos M; Melief CJ; Speiser DE; Coukos G
Immunotherapy; 2012 Aug; 4(8):761-72. PubMed ID: 22947003
[TBL] [Abstract][Full Text] [Related]
9. Microarray analysis for a comprehensive immunological-status evaluation during cancer vaccine immune monitoring.
Monsurrò V; Marincola FM
J Biomed Biotechnol; 2011; 2011():307297. PubMed ID: 21969803
[TBL] [Abstract][Full Text] [Related]
10. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.
Li X; Shao C; Shi Y; Han W
J Hematol Oncol; 2018 Feb; 11(1):31. PubMed ID: 29482595
[TBL] [Abstract][Full Text] [Related]
11. Radiation and Immune Checkpoint Blockade: From Bench to Clinic.
Shabason JE; Minn AJ
Semin Radiat Oncol; 2017 Jul; 27(3):289-298. PubMed ID: 28577836
[TBL] [Abstract][Full Text] [Related]
12. Immunological monitoring of the tumor immunoenvironment for clinical trials.
Malyguine AM; Strobl SL; Shurin MR
Cancer Immunol Immunother; 2012 Feb; 61(2):239-247. PubMed ID: 22080408
[TBL] [Abstract][Full Text] [Related]
13. Quantifying the anti-tumor immune response in patients receiving immunotherapy.
Caushi JX; Smith KN
Discov Med; 2017 Aug; 24(130):59-68. PubMed ID: 28950076
[TBL] [Abstract][Full Text] [Related]
14. Assessing the interactions between radiotherapy and antitumour immunity.
Grassberger C; Ellsworth SG; Wilks MQ; Keane FK; Loeffler JS
Nat Rev Clin Oncol; 2019 Dec; 16(12):729-745. PubMed ID: 31243334
[TBL] [Abstract][Full Text] [Related]
15. Combined Immune Checkpoint Blockade.
Drake CG
Semin Oncol; 2015 Aug; 42(4):656-62. PubMed ID: 26320068
[TBL] [Abstract][Full Text] [Related]
16. The Role of Surgical Pathology in Guiding Cancer Immunotherapy.
Lovitch SB; Rodig SJ
Annu Rev Pathol; 2016 May; 11():313-41. PubMed ID: 27193453
[TBL] [Abstract][Full Text] [Related]
17. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
18. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
Gnjatic S; Bronte V; Brunet LR; Butler MO; Disis ML; Galon J; Hakansson LG; Hanks BA; Karanikas V; Khleif SN; Kirkwood JM; Miller LD; Schendel DJ; Tanneau I; Wigginton JM; Butterfield LH
J Immunother Cancer; 2017; 5():44. PubMed ID: 28515944
[TBL] [Abstract][Full Text] [Related]
19. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy.
Song Y; Li Z; Xue W; Zhang M
Immunotherapy; 2019 Apr; 11(6):515-529. PubMed ID: 30860441
[TBL] [Abstract][Full Text] [Related]
20. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
